Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.

The approval was based on data from a single-arm, phase 3 trial. The US Food and Drug Administration (FDA) has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft ...

There is no indication that Luigi Mangione, the man charged with killing UnitedHealthcare CEO Brian Thompson, was ever a client of UnitedHealthcare, according to authorities.

Though lung cancer survival rates are improving, lung cancer is still the leading cause of cancer deaths in the US.

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

The risk of melanoma-related death is greater for patients with primary tumors that are 0.8-1.0 mm thick than for patients with thinner tumors, data suggest.

Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, ...

(HealthDay News) — President-elect Donald Trump is calling for an end to daylight saving time, a practice he described as inconvenient and costly. “The Republican Party will use its best efforts to ...

The US Food and Drug Administration (FDA) has approved Unloxcyt (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are ...